Advancing the use of new approach methodologies for assessing teratogenicity: Building a tiered approach

M Burbank1, F Gautier1, N Hewitt2

  • 1L'Oréal Research & Innovation, France.

Insights

New Approach Methodologies (NAMs) effectively assess chemical teratogenicity. Combining three methods—in silico DART, devTox, and Zebrafish Embryotoxicity Test—significantly improved predictive accuracy for developmental toxicity evaluations.

Area of Science:

  • Toxicology
  • Developmental Biology
  • Computational Chemistry

Background:

  • New Approach Methodologies (NAMs) are crucial for evaluating new ingredient safety.
  • Assessing reproductive toxicity and teratogenicity is a high priority due to mechanistic complexity.

Purpose of the Study:

  • To screen chemicals for teratogenic potential using multiple in silico and in vitro models.
  • To evaluate the sensitivity and specificity of individual and combined NAMs for teratogenicity prediction.

Main Methods:

  • Screening of 46 non-teratogenic and 39 teratogenic chemicals.
  • Utilized the OECD QSAR Toolbox's DART model, devTox quickPredict™ assay, and Zebrafish Embryotoxicity Test (ZET).
  • Applied a "2 out of 3 rule" and a decision tree approach for combined analysis.

Main Results:

  • Individual assays showed varying sensitivity and specificity (DART: 94.7%/84.1%, devTox: 86.1%/35.6%, ZET: 77.8%/76.7%).
  • Combined "2 out of 3 rule" improved sensitivity to 96.0% and specificity to 71.4%.
  • A decision tree approach for 85 chemicals demonstrated 90% predictivity and robustness.

Conclusions:

  • All three NAMs demonstrated good sensitivity and specificity.
  • Combining assay results, particularly via a "2 out of 3 rule" or decision tree, enhances predictive accuracy for teratogenic potential.
  • A tiered decision tree approach offers a robust strategy for evaluating chemical teratogenicity.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K